# An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia

> **NCT02320032** · PHASE1 · COMPLETED · sponsor: **Alkermes, Inc.** · enrollment: 140 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Aripiprazole Lauroxil

## Key facts

- **NCT ID:** NCT02320032
- **Lead sponsor:** Alkermes, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2018-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02320032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02320032, "An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02320032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*